Mismatched Tech And Demand Behind Korea’s Slow Pharma AI Progress

'Trial And Error' Process

The new head of South Korea’s AI Drug Development Support Center talks about the country’s activities and market trends in the field, why the otherwise tech-savvy country is still lagging and what is needed to boost collaboration and the availability of big data.

artificial intelligence
South Korea’s AI Drug Development Still 'Immature' • Source: Alamy

Artificial intelligence-driven new drug development, which aims to maximize R&D efficiency, has emerged as a key future strategy for South Korean pharma firms, as the huge time and cost required to discover and develop new drugs serves as a major barrier for domestic players.

Although Korean companies have been actively securing AI technology through partnerships over the past few years, their progress has been...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia